Tag: cancer

For media and investors only

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Arvinas, Inc. (NASDAQ:ARVN), Semler Scientific Inc. (NASDAQ:SMLR), and Abacus Global Management, Inc. (NASDAQ:ABL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET.

LOUISVILLE, Ky., June 23, 2025 (GLOBE NEWSWIRE) -- Onco360^®, the nation’s leading independent specialty pharmacy, has been selected as a specialty pharmacy partner by Deciphera Pharmaceuticals, LLC for ROMVIMZA^™ (vimseltinib), which has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.¹ This indication was approved based on the Phase III MOTION study of ROMVIMZA in patients with tenosynovial giant cell tumor (TGCT).²

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

En attendant la décision finale de la Commission européenne, le régime offre une nouvelle norme de soins pour les patients éligibles atteints d’LMC^1,2